Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Akari Therapeutics PLC

AKTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$7.54

▲ +7.56%

Market Cap $14.68M · Vol 12.65K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$14.68M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

41.35

Momentum

Beta

1.35

vs Market

52W High

$49.20

84.67% below

52W Low

$3.03

148.84% above

Volume

12.65K

Avg 12.21K

P/B

0.46

Price-to-book

ROE

N/A

Return on equity

Free Float

82.80%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Akari Therapeutics PLC (AKTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AKTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.71%

-43.82%

+103.78%

-19.10%

YTD

-34.78%

-80.70%

-95.00%

-99.44%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-17,298,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-37.18% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.46
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	3.89B

Technical Indicators

50-Day SMA	$10.81
200-Day SMA	$11.19
RSI (14)	41.35
Beta	1.35
52-Week High	$49.20
52-Week Low	$3.03

Volume Today	12.65K
Avg Daily Volume (30D)	12.21K
Relative Volume	1.04x
Volatility (10D)	110.29
Volatility (30D)	140.19
Free Float	82.80%

Analyst Consensus

BUY

Current Price $7.54

Mean Target $32.33

52W Low$3.03 52W High$49.20

Current

Target

$3.03 $49.20

Current Analyst target

+328.82% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG003PMV510

ISINUS00972G4055

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.